• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血压控制结果。

Outcome of blood pressure control.

作者信息

Wilhelmsen L

机构信息

Department of Medicine, Ostra Hospital, University of Göteborg, Sweden.

出版信息

Qual Assur Health Care. 1990;2(3-4):271-8. doi: 10.1093/intqhc/2.3-4.271.

DOI:10.1093/intqhc/2.3-4.271
PMID:1983247
Abstract

Elevated blood pressure (hypertension) is associated with increased risk for several complications, and the risk is gradually increasing from the lowest to the highest blood pressure levels. Elevated blood pressure is associated with metabolic and other abnormalities which are not affected by antihypertensive treatment. The majority of cardiovascular complications are found among individuals with only moderately elevated blood pressure levels. The antihypertensive treatment principles of today are effective against stroke but considerably less so against coronary heart disease complications. A programme launched by WHO Europe has measured the awareness of hypertension in various communities, the adequacy of care, the patients' satisfaction with the care, physicians' knowledge and attitudes and the utilization of hypotensive drugs. The impact of antihypertensive treatment on stroke and coronary heart disease, which latter are the most common, is reviewed. Quality of life effects of blood pressure treatment as well as some economic aspects are discussed.

摘要

血压升高(高血压)与多种并发症风险增加相关,且风险从血压最低水平到最高水平逐渐升高。血压升高与代谢及其他异常有关,而这些异常不受降压治疗影响。大多数心血管并发症见于血压仅中度升高的个体。当今的降压治疗原则对预防中风有效,但对冠心病并发症的效果则要差得多。世卫组织欧洲区域发起的一项计划,对各社区的高血压知晓情况、治疗的充分性、患者对治疗的满意度、医生的知识与态度以及降压药物的使用情况进行了评估。本文综述了降压治疗对中风和冠心病(后者最为常见)的影响。还讨论了血压治疗对生活质量的影响以及一些经济方面的问题。

相似文献

1
Outcome of blood pressure control.血压控制结果。
Qual Assur Health Care. 1990;2(3-4):271-8. doi: 10.1093/intqhc/2.3-4.271.
2
Recommended treatment protocols to improve management of hypertension globally: A statement by Resolve to Save Lives and the World Hypertension League (WHL).改善全球高血压管理的推荐治疗方案:“决心拯救生命”组织与世界高血压联盟(WHL)的声明
J Clin Hypertens (Greenwich). 2018 May;20(5):829-836. doi: 10.1111/jch.13280. Epub 2018 Apr 27.
3
Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey.医生对血压控制的态度:来自支持高血压认知和研究在欧洲范围内调查的结果。
J Hypertens. 2011 Aug;29(8):1633-40. doi: 10.1097/HJH.0b013e328348c934.
4
Hypertension--when is the clinical problem solved? When patients are rendered normotensive.高血压——临床问题何时得到解决?当患者血压恢复正常时。
Cardiology. 1994;85 Suppl 1:58-64. doi: 10.1159/000176761.
5
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.塞利洛尔和阿替洛尔在高血压患者心血管疾病一级预防中的健康效益及成本效益预测模型
Pharmacoeconomics. 1997 Sep;12(3):384-408. doi: 10.2165/00019053-199712030-00010.
6
7
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.对高血压合并左心室肥厚患者基于氯沙坦与基于阿替洛尔治疗的经济学评估:洛沙坦干预降低终点事件(LIFE)研究在荷兰的适应性研究结果
Clin Ther. 2007 May;29(5):963-971. doi: 10.1016/j.clinthera.2007.05.014.
8
9
Modification of cardiovascular risk factors during antihypertensive treatment: current and new approach trends. The urapidil experience.降压治疗期间心血管危险因素的改善:当前及新的方法趋势。乌拉地尔的经验。
Blood Press Suppl. 1994;4:49-52.
10
Lessons from worldwide experience with hypertension control.
J Hum Hypertens. 1996 Feb;10 Suppl 1:S21-5.

引用本文的文献

1
Selective versus nonselective beta adrenoceptor antagonists in hypertension.高血压治疗中选择性与非选择性β肾上腺素能受体拮抗剂的比较
Pharmacoeconomics. 1995 Dec;8(6):513-23. doi: 10.2165/00019053-199508060-00006.